… ProQR’s Drug Candidate QRX-421 for Usher Syndrome Receives … Orphan Drug Designation from FDA and EMA Key Updates ProQR’s drug candidate QRX-421 for Usher syndrome receives …
… ProQR’s Drug Candidate QRX-411 for Usher Syndrome Receives … Orphan Drug Designation from FDA and EMA Key Updates ProQR’s QRX-411 receives Orphan Drug Designation by the FDA …
… ProQR’s Drug Candidate QR-110 for Leber’s Congenital … LEIDEN, the Netherlands, June 01, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that … mutation,” said Daniel de Boer, Chief Executive Officer of ProQR. “Obtaining orphan drug designations from EMA and FDA …
… will provide up to $7.5 million in funding to develop ProQR’s candidate QR-421a for Usher syndrome type 2A … people with USH2A mutations. The study — known as RUSH2A (“R” stands for “rate of progression”) — was launched in 2017 …
… ProQR Announces Annual Meeting of Shareholders LEIDEN, … be made available in the “Investors & Media” section of ProQR’s website ( www.proqr.com ) under “Financial Information”. The documents …
… ProQR Announces Highlights from Analyst Event LEIDEN, … is available from the “Investors & Media” section of ProQR’s website ( www.proqr.com ) under “ Events ”. Highlights from today’s …
… ProQR Announces Annual Meeting of Shareholders LEIDEN, the … be made available in the ‘Investor Relations’ section of ProQR’s website ( www.proqr.com ) under ‘ Financial Information ’. The …
… ProQR Announces Annual Meeting of Shareholders LEIDEN, the … be made available in the ‘Investor Relations’ section of ProQR’s website ( www.proqr.com ) under ‘ Financial Information ’. The …
… ProQR Announces Annual Meeting of Shareholders Leiden, … or will be made available in the “Investors” section of ProQR’s website ( www.proqr.com ) under “Financial Information”. The documents …